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Abs tract
Ai m: Determine whether patients with Alzheimer’s disease 
demonstrating functional and cognitive decline, following 
24–48 weeks of open-label treatment with 9.5 mg/24 h (10 
cm2) rivastigmine patch, benefit from a dose increase in a 
double-blind (DB) comparative trial of two patch doses. 
Methods: Patients meeting prespecified decline criteria 
were randomized to receive 9.5 or 13.3 mg/24 h (15 cm2) 
patch during a 48-week, DB phase. Coprimary outcomes 
were change from baseline to week 48 on the Instrumental 
Activities of Daily Living domain of the Alzheimer’s Disease 
Cooperative Study–Activities of Daily Living (ADCS-IADL) 
scale and the Alzheimer’s Disease Assessment Scale– 
cognitive subscale (ADAS-cog). Safety and tolerability were 
assessed. Results: Of 1,584 patients enrolled, 567 met de-
cline criteria and were randomized. At all timepoints, ADCS-
IADL and ADAS-cog scores favoured the 13.3 mg/24 h patch. 
The 13.3 mg/24 h patch was statistically superior to the 9.5 
mg/24 h patch on the ADCS-IADL scale from week 16 (p = 
0.025) onwards including week 48 (p = 0.002), and ADAS-
cog at week 24 (p = 0.027), but not at week 48 (p = 0.227). No 
unexpected safety concerns were observed. Conclusions: 
The 13.3 mg/24 h rivastigmine patch significantly reduced 
deterioration in IADL, compared with the 9.5 mg/24 h patch, 
and was well tolerated. Copyright © 2012 S. Karger AG, Basel
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Int roduction
Alzheimer’s disease (AD) is the most common cause 
of dementia, and there is an urgent need to manage af-
fected patients optimally. The pathophysiology of AD is 
complex and includes degeneration of the cortically pro-
jecting cholinergic system, contributing to cognitive im-
pairment and functional decline [1]. Functional decline 
is an important predictor of caregiver burden [2] and 
is also a strong risk factor for nursing home placement 
or the institutionalization of patients with AD [3–5]. 
Cholinesterase inhibitors are the first-line treatment for 
AD and provide symptomatic relief by increasing cholin-
ergic function in the brain [6].
Rivastigmine is the only cholinesterase inhibitor 
available in a transdermal patch formulation, in ad-
dition to oral capsules, that is approved for the symp-
tomatic treatment of mild-to-moderate AD in the USA 
and many other countries worldwide [7–11]. Both riv-
astigmine formulations are also widely approved for 
the treatment of Parkinson’s disease dementia [12, 13]. 
Previous pharmacokinetic studies have demonstrated 
that once daily transdermal administration of rivastig-
mine provides continuous drug delivery, reducing fluc-
tuations in drug plasma concentration, with improved 
tolerability compared with twice daily rivastigmine 
capsules [14–16]. A large, 24-week, randomized, mul-
ticentre, placebo-controlled, double-blind (DB) clini-
cal study (IDEAL; Investigation of transDermal Exelon 
in ALzheimer’s disease) established the 9.5 mg/24 h 
(10 cm2) rivastigmine patch as the currently recommend-
ed target maintenance dose in the treatment of patients 
with mild-to-moderate AD [8]. In the IDEAL study, the 
9.5 mg/24 h patch was shown to have comparable effica-
cy to 12 mg/day capsules, but with improved tolerability, 
fewer withdrawals due to gastrointestinal (GI) adverse 
events (AEs) and threefold lower incidences of nausea 
and vomiting [8], allowing most patients on the 9.5 mg/
24 h patch to achieve their target dose (95.9 vs. 64.4%, re-
spectively) [17]. As the efficacy of rivastigmine has been 
shown to be dose dependent [18, 19], higher doses may 
provide additional benefits compared with currently ap-
proved doses [3]. The 13.3 mg/24 h (15 cm2) patch has 
the potential to provide access to greater efficacy, while 
ensuring a lower incidence of GI AEs than may be ex-
pected with a comparable oral dose.
The objective of this study was to compare the effica-
cy, safety and tolerability of a higher dose of the rivastig-
mine patch with that of the current maintenance dose 
(13.3 vs. 9.5 mg/24 h) in patients with mild-to-moderate 
AD, who had shown functional and cognitive decline on 
the 9.5 mg/24 h patch during an initial open-label (IOL) 
phase.
Methods
Patients
Patients meeting the inclusion criteria for this study were 
women (not of child-bearing potential) or men aged 50–85 
years with a diagnosis of dementia of the Alzheimer’s type 
according to the Diagnostic and Statistical Manual of Mental 
Disorders, 4th edition [20], and probable AD according to 
the criteria of the National Institute of Neurological and 
Communicative Disorders and Stroke and the Alzheimer’s 
Disease and Related Disorders Association [21]. The patients 
included in the study had Mini-Mental State Examination 
(MMSE) scores of ≥10 and ≤24 [22]. They were required to be 
living with someone in the community or be in daily contact 
with a responsible caregiver, if living alone.
Exclusion criteria consisted of: dementia or medical or 
neurological conditions other than AD that could interfere 
with the evaluation of patient response to the study medica-
tion; current diagnosis of uncontrolled seizure disorder; se-
vere/unstable cardiovascular disease; bradycardia (≤50 bpm), 
sick-sinus syndrome or conduction defects; acute, severe or 
unstable asthmatic conditions; uncontrolled peptic ulceration/
GI bleeding within the previous 3 months; clinically significant 
urinary obstruction; allergy to vitamin E-containing products; 
sensitivity to cholinergic compounds or a skin lesion/disorder 
that would prevent transdermal patch use; a history (past 5 
years) of malignancy of any organ system, unless stable, and 
a history or current diagnosis of cerebrovascular disease. Also 
prohibited was the use of cholinesterase inhibitors or other ap-
proved AD treatments for 2 weeks prior to study enrolment, 
with the exception of stable memantine treatment (if taken for 
≥3 months prior to study entry), and the use of investigational 
drugs, new psychotropic medications or dopaminergic agents, 
and anticholinergics if not taken at a stable dose, within the 4 
weeks prior to receiving study treatment.
Patients were enrolled from 147 research centres in 7 coun-
tries: the USA (64 centres), Canada (11), Italy (34), Germany 
(24), France (8), Switzerland (3) and Spain (3). The study pro-
tocol was reviewed by the representative ethics committee for 
each centre. The study was designed and implemented in ac-
cordance with Good Clinical Practice and the local regulations 
and ethical principles laid down in the Declaration of Helsinki. 
All patients, or a legally acceptable representative, and caregiv-
ers provided written informed consent prior to participating 
in the study.
Study Design and Interventions
The OPTIMA (OPtimizing Transdermal Exelon In Mild-
to-moderate Alzheimer’s disease) study was a 72- to 96-week 
multicentre trial, composed of a 24- to 48-week IOL phase 
followed by a 48-week randomized, DB, parallel-group phase 
(Clinicaltrials.gov identifier NCT00506415).
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Patients meeting the eligibility criteria were enrolled into 
a 24- to 48-week IOL phase; treatment was initiated with 
the 4.6 mg/24 h (5 cm2) rivastigmine patch. Patients were ti-
trated to the once daily 9.5 mg/24 h patch after 4 weeks and 
were maintained on this dose for the remainder of the IOL 
phase. IOL baseline efficacy and safety assessments were per-
formed on day 1, prior to administration of the first dose of 
study drug. The inclusion criteria for entering the DB phase 
were functional and cognitive decline during the IOL phase. 
Patients were evaluated at weeks 24, 36 and 48 of the IOL 
phase for functional decline (by investigator judgement) and 
cognitive decline (≥2-point decline in MMSE score from the 
previous visit, or ≥3-point decline in MMSE score from base-
line). Patients meeting the decline criteria at week 24, 36 or 48 
then entered the DB phase and were randomized 1:1 to receive 
9.5 mg/24 h or 13.3 mg/24 h rivastigmine patch, and were 
maintained at their target dose for an additional 48 weeks. 
Dose adjustments and interruptions were permitted for pa-
tients unable to tolerate the specified dose, until tolerability 
improved. Only patients tolerating the 9.5 mg/24 h patch were 
eligible to enter the DB phase. Patients who did not meet the 
decline criteria were given the option to enter an extended 
open-label (EOL) treatment phase with the 9.5 mg/24 h riv-
astigmine patch.
Primary Outcomes
Primary outcomes were the change from baseline of the DB 
phase to week 48 of the DB phase on the Instrumental Activities 
of Daily Living domain (items 7–23) of the Alzheimer’s Disease 
Cooperative Study–Activities of Daily Living (ADCS-IADL) 
scale [23] and the Alzheimer’s Disease Assessment Scale–
cognitive subscale (ADAS-cog) [24].
Secondary Outcomes
Secondary outcomes were the time to functional decline on 
the ADCS-IADL scale during the 48-week DB phase, and the 
change from DB baseline to week 48 of the DB phase in the 
Trail Making Test parts A and B (TMT-A and TMT-B) [25, 26], 
the 10-item Neuropsychiatric Inventory (NPI-10) [27], and the 
NPI-caregiver distress scale (NPI-D) [28].
Time to functional decline was the interval between the DB 
baseline to first decline on the ADCS-IADL scale. Decline was 
defined by either a ≥1-point decrease at a visit and confirmed 
by the following visit, or a ≥2-point decrease in total ADCS-
IADL score from DB baseline.
Safety evaluations included the frequency of AEs and seri-
ous AEs (SAEs), the discontinuation rate due to AEs, monitor-
ing of vital signs and 12-lead electrocardiogram.
Concomitant Medications
Medications and/or therapies that were started prior to 
the first dose of study drug, and concomitant medications/
therapies that were administered on or after the first dose of 
study drug were coded using the World Health Organization 
Drug Reference List that employs the Anatomical Therapeutic 
Chemical classification system.
Sample Size, Randomization and Blinding
It was estimated that a sample size of 410 patients in each 
group at the end of the DB phase was required to have 85% power 
to detect a treatment difference of 1.9 points on the coprimary 
efficacy variables, the ADCS-IADL and the ADAS-cog, in the 
intent-to-treat (ITT) population. This was assuming a common 
standard deviation of 8 for both the coprimary efficacy variables, 
using a two-group t test with a 0.05 two-sided significance level. 
A correlation of 0.35 between the coprimary efficacy variables 
was assumed. To adjust for 5% of patients who may not be in-
cluded in the ITT population, a total of 864 patients (432 per 
group) was estimated to be needed at the time of DB randomiza-
tion (the end of the IOL phase). Based on the long-term study of 
rivastigmine capsules [29], it was assumed that the percentage 
of patients who would show cognitive decline in the IOL phase 
would be 55%. Thus, it was estimated that 1,571 patients would 
be needed to be enrolled in the IOL phase to ensure that at least 
864 declining patients would be available for randomization.
Randomization of patients in the DB phase was performed 
using an interactive voice response system, which uses a vali-
dated system to automate the assignment of patients to ran-
domization numbers.
Treatment was not blinded during the IOL phase; howev-
er, from the time of randomization in the DB phase, patients, 
investigator staff, individuals performing the assessments and 
data analysts all remained blind to the identity of the treatment. 
A DB, double-dummy design was used whereby all patients re-
ceived an identical-looking patch of each size: patients random-
ized to receive the 9.5 mg/24 h patch dose were supplied with 
9.5 mg/24 h (10 cm2) rivastigmine patches and 15 cm2 placebo 
patches. Patients randomized to receive the 13.3 mg/24 h patch 
dose were supplied with 13.3 mg/24 h (15 cm2) rivastigmine 
patches and 10 cm2 placebo patches. Unblinding occurred only 
in the case of patient emergencies and at the end of the study.
Statistical Analysis
In all efficacy analyses of the DB phase, patient data were 
analysed according to the treatment randomized. The prima-
ry analysis was based on the ITT population in the DB phase 
(ITT-DB) using a last-observation carried forward (LOCF) 
imputation [ITT(DB)-LOCF]. The ITT-DB population con-
sisted of all patients who received at least 1 dose of study drug 
and had at least 1 postrandomization assessment for both 
coprimary efficacy variables (ADCS-IADL and ADAS-cog) 
during the DB phase. The primary analysis was also conducted 
using observed cases (OC) based on the ITT-DB population 
[ITT(DB)-OC], as well as based on the per-protocol (PP) pop-
ulation using both LOCF and OC approaches [PP(DB)-LOCF 
and -OC]. The PP-DB population was defined as all ITT-DB 
patients without any major protocol deviations and who had at 
least 1 postrandomization assessment for both coprimary ef-
ficacy variables (ADCS-IADL and ADAS-cog) on or after DB 
week 24 on target dose, during the DB phase. The safety popu-
lation during the DB phase consisted of all patients who were 
randomized, who received at least 1 dose of study drug and 
who had at least 1 postrandomization safety assessment during 
the DB phase. Safety data were analysed descriptively accord-
ing to the treatment received and the study period.
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Changes from baseline on scores of the ADCS-IADL and 
ADAS-cog were compared between treatment groups using least-
squares (LS) means derived by analysis of covariance using the 
following explanatory variables: treatment, country and corre-
sponding baseline score. To assess the robustness of both copri-
mary efficacy variable analyses, comparison of the treatments was 
also performed with LOCF via the non-parametric van Elteren 
test, stratified by country as a supportive analysis [ITT(DB)-
LOCF]. Sensitivity analyses were performed for both coprimary 
efficacy variables based on a mixed-effects repeated measures 
model examining the treatment group differences as a function 
of time [ITT(DB)-OC]. Additional sensitivity analyses were per-
formed to evaluate the possibility that missing primary efficacy 
measure data may not be missing at random utilizing multiple 
imputations under missing at random (MAR) and different miss-
ing not at random (MNAR) scenarios using penalty scores.
The time to functional decline as assessed by the ADCS-
IADL over the 48-week DB phase was analysed using the 
log-rank test for interval censored data, based on the ITT 
population without imputation [ITT(DB)-OC]. A Cochran-
Mantel-Haenszel test, with country as a stratification variable, 
was used for comparison of the percentage of patients show-
ing decline in the ADCS-IADL in the two treatment groups. 
Additional supportive analyses were performed for time to 
functional decline and percentage of subjects with functional 
decline during the DB phase on the PP-DB population. Change 
from DB baseline in total time to perform the TMT-A and 
TMT-B, and in the NPI-10 and NPI-D total scores were com-
pared between treatment groups using LS means derived by 
analysis of covariance [ITT(DB)-LOCF and -OC populations] 
with similar explanatory variables to those used for the analy-
ses on coprimary efficacy variables.
Results
Participants
The first patient was screened in June 2007, and the 
last patient completed the study in May 2011. Of the 1,979 
patients screened, 1,584 were enrolled in the IOL phase 
(USA, 589 patients; Canada, 164; Italy, 356; Germany, 
268; France, 129; Switzerland, 40; Spain, 38), and 1,582 
were exposed to study drug. In total, 567 patients (35.8%) 
were classified as decliners and were randomized into the 
DB phase: 280 to the 13.3 mg/24 h rivastigmine patch 
and 287 to the 9.5 mg/24 h rivastigmine patch (fig. 1). 
One patient in the 9.5 mg/24 h rivastigmine patch group 
did not receive the randomized study drug and discon-
tinued before the start of the DB phase. The reason for 
discontinuation of this patient was documented as part 
of the IOL phase. In the 13.3 mg/24 h patch group, 207 
participants (73.9%) completed the DB phase, compared 
with 203 participants (70.7%) in the 9.5 mg/24 h patch 
group. The most common reasons for discontinuation 
during the DB phase were similar in both the 13.3 and 
the 9.5 mg/24 h patch groups (fig. 1).
The ITT-DB population comprised 265 and 271 
patients in the 13.3 and 9.5 mg/24 h patch groups, re-
spectively. The safety population during the DB phase 
comprised 280 and 283 patients in the 13.3 and 9.5 
mg/24 h patch groups, respectively. Baseline demograph-
ics and background characteristics were comparable be-
tween the two treatment groups (table 1). At DB baseline, 
the mean and median durations of time since the first 
AD symptom had been noticed by the patient/caregiver 
or was diagnosed by a physician were slightly longer in 
the 9.5 mg/24 h group than in the 13.3 mg/24 h group 
(table 1). At IOL baseline, the mean MMSE score tended 
to be lower in decliners (i.e. those randomized in the DB 
phase) compared with non-decliners (i.e. those who en-
tered the extended open-label phase).
Dosing
During the DB phase, the mean exposure to study 
drug was similar in both the 13.3 mg/24 h (41.4 ± 14.3 
weeks) and 9.5 mg/24 h (41.3 ± 13.6 weeks) treatment 
groups (safety population during the DB phase).
Primary Efficacy Assessments
ADCS-IADL Scores
Both treatment groups showed decline on the ADCS-
IADL total score from baseline during the 48-week DB 
phase. This decline was less at all time points in patients 
randomized to receive the 13.3 mg/24 h rivastigmine 
patch. Significantly less decline was observed on ADCS-
IADL total scores at weeks 16, 24, 32 and 48 (primary end 
point; p = 0.025, 0.005, <0.001 and 0.002, respectively) in 
patients receiving the 13.3 mg/24 h patch compared with 
the 9.5 mg/24 h patch (fig. 2a; table 2).
ADAS-cog Scores
Both treatment groups demonstrated cognitive de-
cline from baseline at weeks 24–48 in the ITT(DB)-
LOCF population. At all time points, cognitive decline 
was less in the 13.3 mg/24 h rivastigmine patch group 
compared with the 9.5 mg/24 h patch group (fig. 2b; table 
2). Between-group differences did not reach significance 
at week 48 (p = 0.227); significant treatment differenc-
es in favour of the 13.3 mg/24 h patch were observed at 
week 24 (p = 0.027).
Results consistent with those from the primary analy-
ses were documented on the ADCS-IADL and ADAS-cog 
in the OC analysis (table 2), and several sensitivity analy-
ses (mixed-effects repeated measures model, van Elteren 
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test, and multiple imputations under MAR and various 
MNAR scenarios). In the PP-DB population (LOCF and 
OC analyses), significantly less decline was observed at all 
time points on the ADCS-IADL (weeks 8–48), and less 
cognitive decline was observed at all time points on the 
ADAS-cog, although between-group differences did not 
reach significance.
Secondary Efficacy Assessments
Time to Functional Decline
Functional decline on the ADCS-IADL [ITT(DB)-
OC] tended to occur later in the 13.3 mg/24 h patch 
group than in the 9.5 mg/24 h patch group, although the 
observed difference did not reach significance. Over the 
48-week DB phase, the proportion of patients with func-
Fi g . 1. Study design and patient flow through the study. N = Number of patients in the population; n = number 
of patients with an assessment. a A patient with multiple reasons for screening failure is counted in each category. 
b One patient (decliner) was randomized to receive the 9.5 mg/24 h rivastigmine patch but was not treated with 
the randomized study drug in the DB phase. The patient discontinued before the start of the DB phase, and the 
reason for discontinuation was documented in the IOL phase. Data relating to patients entering the EOL phase 
will be described separately in further publications.
26.1% discontinued (n = 73)
Reason for discontinuation:
AE (n = 28)
Subject withdrew consent (n = 17)
Unsatisfactory therapeutic effect (n = 13)
Lost to follow-up (n = 6)
Protocol deviation (n = 3)
Death (n = 3)
Administrative problem (n = 2)
Subject’s condition no longer
 requires study drug (n = 1)
Reason for discontinuation:
AE (n = 33)
Subject withdrew consent (n = 20)
Unsatisfactory therapeutic effect (n = 13)
Death (n = 5)
Protocol deviation (n = 5)
Lost to follow-up (n = 4)
Administrative problem (n = 3)
Failed screening (n = 395)a
Did not meet diagnostic/severity criteria (n = 140)
Other (n = 80)
Unacceptable test procedure result (n = 59)
Subject withdrew consent (n = 50)
Unacceptable medical history/concurrent diagnosis (n = 48)
Unacceptable laboratory value (n = 44)
Intercurrent medical event (n = 18)
Unacceptable use of excluded medications/therapies (n = 9)
28.9% discontinued (n = 83)
73.9% completed the study
(n = 207)
70.7% completed the study
(n = 203)
13.3 mg/24 h patch
(N = 280)
9.5 mg/24 h patch
(N = 287)b
Decliners randomized into DB phase
(N = 567)
Non-decliners continuing to receive
9.5 mg/24 h patch in the EOL phase
(n = 457)
Completed IOL phase
(N = 1,085)
Enrolled into IOL phase (n = 1,584)
(Exposed to study drug 9.5 mg/24 h; N = 1,582)
Screened
(N = 1,979)
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tional decline was also lower in the 13.3 mg/24 h patch 
group (77.0%) compared with the 9.5 mg/24 h patch 
group (81.2%), but the difference was not statistically 
significant.
Other Secondary Efficacy Assessments
There were no significant between-group differences 
on the other secondary efficacy outcomes. The mean time 
to complete the TMT-A and TMT-B was slightly longer 
in the 9.5 mg/24 h patch group compared with the 13.3 
mg/24 h patch group at DB baseline. Patients in the 13.3 
mg/24 h patch group had numerically smaller increases 
in time to complete the TMT-A at DB weeks 24 and 48 
compared with those in the 9.5 mg/24 h patch group. The 
greatest differences between groups were observed at 
week 24; differences in LS means (DLSM) were not sig-
nificant for the ITT(DB)-LOCF (table 3) or -OC popula-
tions (data not shown). The 13.3 mg/24 h patch group 
had numerically larger increases in time to complete the 
TMT-B at weeks 24 and 48 compared with the 9.5 mg/
Table 1. Patient demographics and background characteristics (IOL baseline and DB baseline)
IOL phase DB phase
non-decliners
(n = 459)
decliners
(n = 567)
discontinued
(n = 558)
13 .3 mg/24 h
rivastigmine 
patch
(n = 280)
9.5 mg/24 h 
rivastigmine 
patch
(n = 287)
total
(n = 567)
Mean age, years
 Range
74.6±7.0
52.0–85.0
74.5±7.1
51.0–85.0
75.6±7.3
50.0–85.0
75.6±7.4
54.0–87.0
75.9±6.8
53.0–87.0
75.7±7.1
53.0–87.0
Female patients, n (%) .265 (57.7) .367 (64.7) .360 (64.5) .185 (66.1) .182 (63.4) .367 (64.7)
Race, %
 Caucasian
 Black
 Other
96.3
02.0
01.7
96.6
01.8
01.6
93.5
04.1
02.3
95.0
02.9
02.1
98.3
00.7
01.0
96.6
01.8
01.6
Mean weight, kg
 Range
70.3±14.6a
40.5–119.0
68.7±14.6b
39.0–121.0
68.8±13.6
41.0–124.3
69.5±15.5
38.0–118.4
67.9±13.9
40.0–110.6
68.7±14.7
38.0–118.4
Mean number of years of formal 
education
 Range
10.2±4.0
00.0–23.0
10.6±4.0b
02.0–22.0
10.8±4.2
02.0–25.0
10.5±4.0c
02.0–20.0
10.6±4.0
03.0–22.0
10.6±4.0b
02.0–22.0
Mean time since first AD symptom 
was noticed by patient/caregiver, 
years
 Median
 Range
03.4±2.6
02.7
00.1–19.2
04.1±2.8
03.4
00.2–17.7
03.9±2.9
03.1
00.4–19.4
03.9±2.8
03.2
00.2–17.7
04.3±2.8
03.6
00.3–15.6
04.1±2.8
03.4
00.2–17.7
Mean time since first symptom of 
AD was diagnosed by physician, 
years
 Median
 Range
01.4±1.7
00.7
00.0–10.3
01.9±2.0
01.3
00.0–12.6
01.7±2.0
01.0
00.0–11.9
01.8±1.8
1.25
00.0–10.9
02.0±2.1
01.4
00.0–12.6
01.9±2.0
01.3
00.0–12.6
Mean baseline MMSE score
 Range
18.8±3.3
10.0–24.0
16.9±3.6
10.0–25.0
17.8±3.4
10.0–24.0
14.1±4.8
00.0–24.0
14.2±4.6
02.0–26.0
14.2±4.7
00.0–26.0
Concomitant memantine, n (%) 0.94 (20.5) .183 (32.3) .141 (25.4) 0.92 (32.9) 0.90 (31.8) .182 (32.3)
Results are expressed as means ± SD unless otherwise stated. Decliners = patients meeting the decline criteria during the IOL phase 
who were randomized in the DB phase; non-decliners = patients not meeting the decline criteria during the IOL phase who then entered 
the EOL phase. Demographic information was collected at screening (IOL baseline) for the non-decliners vs. the decliners. For the 
decliners randomized into the DB phase, demographic information was collected at DB baseline, the last assessment in the IOL phase.
a n = 458.
b n = 566.
c n = 279.
Dement Geriatr Cogn Disord 2012;33:341–353 347Efficacy and Safety of Higher-Dose 
Rivastigmine Patch (13.3 mg/24 h) in AD
24  h patch group. The greatest DLSM was observed at 
week 24; however, there were no significant differences 
between groups at any time point in the ITT(DB)-LOCF 
(table 3) or -OC populations (data not shown).
Both treatment groups showed slight deterioration or 
no change from baseline at the study end point for both 
the NPI-10 and NPI-D scales. Between-dose treatment 
differences were not significantly different (table 3).
Safety Assessments
Deaths, SAEs and Discontinuations
There were no unexpected safety effects of treatment 
with either rivastigmine patch dose. The incidences of 
SAEs and deaths were similar between treatment groups 
in the DB phase (SAEs: 15.7 and 15.5%, 13.3 and 9.5 
mg/24 h patch, respectively; deaths: 1.1 and 1.8%, 13.3 
and 9.5 mg/24 h patch, respectively). No deaths were 
considered to be related to the study medication. The 
most frequently reported SAEs in the DB phase, by pri-
mary system organ class, were infections and infestations 
(4.6 vs. 4.2%, 13.3 and 9.5 mg/24 h patch, respectively) 
and nervous system disorders (5.0 vs. 3.9%, respectively). 
The incidence of AEs and SAEs leading to discontinu-
ation in the DB phase was lower with the 13.3 mg/24 h 
patch than with the 9.5 mg/24 h patch (AEs leading to 
discontinuation: 9.6 vs. 12.7%, 13.3 and 9.5 mg/24 h 
patch, respectively; SAEs leading to discontinuation: 4.3 
vs. 6.4%, respectively). The most common AEs leading to 
discontinuation were GI disorders, general disorders and 
administration site conditions, and psychiatric disorders.
Incidence of AEs
Overall, in the DB phase AEs were reported in a great-
er proportion of patients in the 13.3 mg/24 h patch group 
than the 9.5 mg/24 h patch group (table 4). The most fre-
quently reported AEs in the DB phase, by primary sys-
tem organ class, were GI disorders (29.3 vs. 19.1%, 13.3 
and 9.5 mg/24 h patch, respectively), psychiatric disor-
ders (25.4 vs. 21.6%, respectively) and nervous system 
disorders (21.4 vs. 18.4%, respectively). Skin and subcu-
taneous tissue disorders were less frequently observed 
with the 13.3 mg/24 h than the 9.5 mg/24 h patch (2.1 vs. 
Fig. 2. LS mean change from baseline 
during the 48-week DB phase on the 
ADCS-IADL (a) and ADAS-cog (b) in the 
ITT(DB)-LOCF population. Error bars 
represent the standard error of the mean; 
* p < 0.05, ** p < 0.001 for 13.3 mg/24 h 
vs. 9.5 mg/24 h rivastigmine patch. The 
differences in LS means, 95% confidence 
intervals and p values are based on an 
analysis of covariance model adjusted for 
country and baseline score (ADCS-IADL 
or ADAS-cog).
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6.0%, respectively). Cholinergic GI AEs were more fre-
quently reported with the 13.3 mg/24 h patch than with 
the 9.5 mg/24 h patch and were most commonly: nau-
sea, vomiting, weight decreased, appetite decreased and 
upper abdominal pain (table 4). When AEs were summa-
rized according to time during the DB phase, i.e. those 
with onset during weeks 1–24 and those with onset dur-
ing weeks 25–48 (>24 weeks), the percentages of patients 
with these events decreased over time in both treatment 
groups, with the exception of ‘weight decreased’. The per-
centage of patients treated for >24 weeks who reported 
an AE of vomiting was comparable in the 13.3 and 9.5 
mg/24 h patch groups (table 4). Application site erythe-
ma and application site pruritus were reported in compa-
rable proportions of patients in the two treatment groups 
(table 4), and the percentage of patients with these events 
decreased over time in both treatment groups. The per-
centage of patients treated for >24 weeks who reported 
an AE of application site erythema or pruritus was lower 
with the 13.3 mg/24 h patch than with the 9.5 mg/24 h 
patch (table 4).
The incidence of AEs leading to a dose adjustment 
or study medication interruption in the DB phase was 
13.9% in the 13.3 mg/24 h patch group and 5.3% in the 
9.5 mg/24 h patch group.
There were no clinically relevant changes from base-
line to the end of the DB phase for any vital sign param-
eter in either treatment group. During the DB phase, the 
incidence of patients experiencing newly occurring elec-
trocardiogram abnormalities was low and was similar in 
the two patch groups (17.5 vs. 15.2%, 13.3 mg/24 h patch 
vs. 9.5 mg/24 h patch).
Concomitant Medications
During the DB phase, a similar percentage of patients 
in both the 13.3 and 9.5 mg/24 h patch groups were re-
ceiving at least 1 drug from 3 prespecified classes of CNS 
medications (antipsychotics, antidepressants or hypnotic/
Table 2. Mean ADCS-IADL and ADAS-cog scores and change from baseline at weeks 24 and 48 in the ITT(DB)-LOCF and ITT(DB)-
OC populations
13.3 mg/24 h 
rivastigmine patch
9.5 mg/24 h 
rivastig mine patch
DLSM p value
n score n score
ADCS-IADL ITT(DB)-LOCF
 Baseline
 Change at week 24
 Change at week 48
265
265
265
27.5
–1.5
–4.4
271
271
271
25.8
–2.8
–6.2
–
1.7 (0.5, 2.9)
2.2 (0.8, 3.6)
–
0.005
0.002
ITT(DB)-OC
 Baseline for week 24
 Change at week 24
 Baseline for week 48
 Change at week 48
232
232
209
209
27.8
–1.0
27.9
–4.6
243
243
198
198
26.3
–3.0
27.6
–6.9
–
2.3 (1.0, 3.6)
–
2.5 (0.8, 4.1)
–
<0.001
–
0.004
ADAS-cog ITT(DB)-LOCF
 Baseline
 Change at week 24
 Change at week 48
264
264
264
34.4
 1.0
 4.1
268
268
268
34.9
 2.2
 4.9
–
–1.3 (–2.5, –0.2)
–0.8 (–2.1, 0.5)
–
0.027
0.227
ITT(DB)-OC
 Baseline for week 24
 Change at week 24
 Baseline for week 48
 Change at week 48
238
238
211
211
34.2
 0.9
33.9
 4.3
238
238
193
193
34.5
 2.1
33.4
 5.3
–
–1.3 (–2.5, 0.1)
–
–1.2 (–2.7, 0.4)
–
0.035
–
0.141
Figures in parentheses indicate 95% confidence limits. DLSM = difference of LS means; n = number of patients with an assessment 
at baseline (last assessment in the IOL phase) and either the corresponding visit (for the OC) or with at least 1 postbaseline assessment 
(for the LOCF). 95% confidence limits and p values are based on an analysis of covariance model adjusted for country and baseline score 
(ADCS-IADL or ADAS-cog).
Dement Geriatr Cogn Disord 2012;33:341–353 349Efficacy and Safety of Higher-Dose 
Rivastigmine Patch (13.3 mg/24 h) in AD
anxiolytics; 30.0 and 31.1%, 13.3 and 9.5 mg/24 h patch 
groups, respectively). Approximately 20% of patients in 
both treatment groups initiated treatment with at least 
one of these medications during the DB phase. Similar 
percentages of patients in both groups initiated treat-
ment with antidepressants (10.0 and 8.5%, 13.3 and 
9.5 mg/24 h patch groups, respectively), antipsychotics 
(8.9 and 9.9%, respectively) and hypnotics/anxiolytics 
(6.1 and 6.4%, respectively). During the DB phase, the 
overall mean duration of treatment with these medica-
tions in the 13.3 and 9.5 mg/24 h patch groups was: 37.0 
and 39.8 weeks for antidepressants; 26.7 and 29.5 weeks 
for antipsychotics; 33.0 and 33.2 weeks for hypnotics/
anxiolytics.
Discussion
In this study, patients with AD demonstrating func-
tional and cognitive decline while receiving the currently 
approved maintenance dose of 9.5 mg/24 h rivastigmine 
as a patch showed additional benefit with titration to the 
higher-dose 13.3 mg/24 h patch.
The 13.3 mg/24 h rivastigmine patch demonstrated 
statistically superior efficacy on functional outcomes over 
the 9.5 mg/24 h patch from week 16 onwards. Patients re-
ceiving the 13.3 mg/24 h patch also showed less decline at 
all time points on the ADAS-cog and demonstrated sta-
tistically superior efficacy over the 9.5 mg/24 h patch at 
week 24 of the DB phase (p = 0.027), but failed to show a 
significant difference at week 48 (coprimary end point). 
Other supportive and sensitivity analyses confirmed the 
results obtained in the ITT-LOCF population. The riv-
astigmine patch has previously been associated with re-
duced caregiver burden [30]. Since functional decline is 
an important predictor of caregiver burden [2], the su-
perior efficacy of the 13.3 mg/24 h patch, particularly on 
IADLs, may translate into clinically important benefits 
for patients and their caregivers.
There were no between-dose statistically significant 
differences in the time to functional decline, and per-
formance on the TMT-A and TMT-B tests for executive 
function. Likewise, no significant effect of the higher-
dose patch was observed on the behavioural scales, the 
NPI-10 and NPI-D. However, numerical trends towards 
greater efficacy of the 13.3 mg/24 h patch were observed 
Table 3. Secondary efficacy outcomes [ITT(DB)-LOCF population]
13.3 mg/24 h 
rivastigmine patch
9.5 mg/24 h 
rivastigmine patch
DLSM p value
TMT-A
 N 0.254 0.258
 Baseline 191.3 199.4 –– –
 Change from baseline at week 24 004.2 010.2 –7.8 (–17.3, 1.7) 0.105
 Change from baseline at week 48 016.3 018.2 –3.8 (–14.3, 6.6) 0.473
TMT-B
 N 0.235 0.236
 Baseline 372.2 380.8 –– –
 Change from baseline at week 24 005.5 000.9 –1.6 (–9.9, 13.1) 0.784
 Change from baseline at week 48 009.3 005.8 –0.8 (–10.1, 11.8) 0.881
NPI-10 
 n 0.265 0.271
 Baseline 012.4 014.4 –– –
 Change from baseline at week 48 001.4 000.9 –0.1 (–1.9, 1.7) 0.927
NPI-D
 n 0.265 0.271
 Baseline 006.5 008.1 –– –
 Change from baseline at week 48 000.6 000.0 –0.2 (–0.7, 1.2) 0.647
Figures in parentheses indicate 95% confidence limits. DLSM = difference of LS means; N = number of patients with an assessment 
at baseline and at least 1 postbaseline assessment; n = number of patients with an assessment at baseline and at the DB end point (week 
48). For patients who were unable to complete the TMT-B, a maximum time of 420 s was recorded.
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in all but one (TMT-B) of these secondary outcomes. 
Interpretation of the TMT-B test results was limited due 
to the fact that the majority of patients were not able to 
perform the test within the given time period at DB base-
line and later assessments. This may contribute to the 
observed lack of treatment effect on the TMT-B since a 
maximum time of 420 s was recorded for these patients. 
The NPI-D provides a reliable measure of caregiver dis-
tress related to neuropsychiatric symptoms and behav-
ioural disturbances [28]; global measures of caregiver 
burden and quality of life were not assessed. However, 
these measures may show treatment-related benefits as 
a result of the reduced decline in the patients’ ability to 
perform IADLs seen in this study.
The selection of a population demonstrating functional 
and cognitive decline was a novel aspect of this trial design, 
and while it more closely represents a ‘real-life’ clinical sce-
nario, the resultant clinical profile of the patients should 
be noted. At the beginning of the DB phase, the mean 
MMSE score for all patients randomized was 14.2 (range 
0.0–26.0) indicating that a large proportion of the patients 
had reached moderate-to-severe stages of AD. The ADAS-
cog is best suited for assessing mild-to-moderate stages of 
dementia [31, 32] due to floor effects in patients with more 
severe AD [31]. The ADAS-cog may not have been sensitive 
enough to detect dose-related differences reliably as patients 
progressed to the later time points of the study. Decline on 
the 9.5 mg/24 h patch in the IOL phase was less than the 
original assumption for the sample size calculation, which 
was based on a long-term study with rivastigmine capsules 
[29]. Although this resulted in a smaller sample size in 
the DB population than anticipated (567 vs. 864 predict-
Table 4. Most frequent (≥3% in any treatment group) AEs in the 48-week DB phase by time period (weeks 0–48, 0–24 and >24), treat-
ment and preferred term (Safety population in the DB phase)
Preferred term Week 0–48 Week 0–24 Week >24
13.3 mg/24 h 
rivastigmine 
patch
(n = 280)
9.5 mg/24 h 
rivastigmine 
patch
(n = 283)
13.3 mg/24 h 
rivastigmine 
patch
(n = 280)
9.5 mg/24 h 
rivastigmine 
patch
(n = 283)
13.3 mg/24 h 
rivastigmine 
patch
(n = 241)
9.5 mg/24 h 
rivastigmine 
patch
(n = 246)
Total 210 (75.0) 193 (68.2) 181 (64.6) 155 (54.8) 102 (42.3) 99 (40.2)
Nausea 034 (12.1) 014 (4.9) 027 (9.6) 010 (3.5) 010 (4.1) 04 (1.6)
Vomiting 029 (10.4) 013 (4.6) 025 (8.9) 008 (2.8) 006 (2.5) 06 (2.4)
Fall 021 (7.5) 017 (6.0) 012 (4.3) 010 (3.5) 009 (3.7) 07 (2.8)
Weight decreased 019 (6.8) 008 (2.8) 007 (2.5) 004 (1.4) 013 (5.4) 05 (2.0)
Application site erythema 018 (6.4) 016 (5.7) 016 (5.7) 013 (4.6) 002 (0.8) 04 (1.6)
Decreased appetite 018 (6.4) 007 (2.5) 015 (5.4) 006 (2.1) 004 (1.7) 01 (0.4)
Diarrhoea 018 (6.4) 013 (4.6) 014 (5.0) 012 (4.2) 004 (1.7) 01 (0.4)
Urinary tract infection 015 (5.4) 012 (4.2) 008 (2.9) 007 (2.5) 008 (3.3) 06 (2.4)
Agitation 014 (5.0) 015 (5.3) 011 (3.9) 009 (3.2) 003 (1.2) 06 (2.4)
Depression 014 (5.0) 013 (4.6) 008 (2.9) 008 (2.8) 006 (2.5) 05 (2.0)
Dizziness 012 (4.3) 002 (0.7) 008 (2.9) 001 (0.4) 004 (1.7) 01 (0.4)
Application site pruritus 011 (3.9) 011 (3.9) 010 (3.6) 008 (2.8) 001 (0.4) 03 (1.2)
Headache 011 (3.9) 011 (3.9) 010 (3.6) 010 (3.5) 001 (0.4) 01 (0.4)
Insomnia 011 (3.9) 007 (2.5) 005 (1.8) 003 (1.1) 006 (2.5) 04 (1.6)
Upper abdominal pain 010 (3.6) 003 (1.1) 008 (2.9) 002 (0.7) 002 (0.8) 01 (0.4)
Anxiety 010 (3.6) 007 (2.5) 006 (2.1) 005 (1.8) 004 (1.7) 02 (0.8)
Confusional state 009 (3.2) 007 (2.5) 005 (1.8) 006 (2.1) 004 (1.7) 01 (0.4)
Hypertension 009 (3.2) 008 (2.8) 007 (2.5) 005 (1.8) 002 (0.8) 03 (1.2)
Urinary incontinence 009 (3.2) 005 (1.8) 006 (2.1) 004 (1.4) 003 (1.2) 01 (0.4)
Psychomotor hyperactivity 007 (2.5) 009 (3.2) 005 (1.8) 007 (2.5) 004 (1.7) 02 (0.8)
Aggression 006 (2.1) 009 (3.2) 003 (1.1) 007 (2.5) 003 (1.2) 02 (0.8)
Results are expressed as numbers of patients reporting an AE during the DB phase, with percentages in parentheses. n = num-
ber of patients in the safety DB population at the beginning of the treatment period. AEs are sorted by descending frequency in the 
13.3 mg/24 h rivastigmine patch group. A patient with multiple occurrences of the same AE within a treatment group was counted only 
once in each period.
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ed), one of the coprimary end points reached significance 
(ADCS-IADL) and the second showed consistent numeri-
cal superiority (ADAS-cog). Specifically, the 13.3 mg/24 h 
patch was statistically superior to the 9.5 mg/24 h patch at 
week 24 on the ADAS-cog, a time point which has typically 
been used as the primary end point in pivotal studies of 
dementia medications [8, 33–35]. In addition, numerical 
improvements in DLSM of 1.3 and 0.8 points in ADAS-
cog at weeks 24 and 48, respectively with the 13.3 mg/24 h 
patch compared with the active comparator (9.5 mg/24 h 
patch) can be considered clinically meaningful, based on 
published data indicating that a decline of approximately 
1–2 points may be expected in patients with mild-to-mod-
erate AD receiving placebo over a 6-month trial period [8, 
35].
The efficacy of cholinesterase inhibitors has previous-
ly been shown to be dose dependent [18, 19], and there 
is increasing awareness surrounding the importance 
of reaching and maintaining optimal therapeutic doses 
[36]. To our knowledge, this study is unique in providing 
DB, randomized data on cholinesterase inhibitor efficacy 
and tolerability extending beyond 24 weeks, in addition 
to providing comparative data on two active doses of the 
same drug, for which there are very few published data 
[37]. Current findings from the OPTIMA trial (up to 
48 weeks of DB treatment) support high-dose efficacy. 
The administration of the higher-dose (13.3 mg/24 h) 
rivastigmine patch had no new or unexpected concerns 
relating to safety and tolerability. The 13.3 mg/24 h patch 
was not associated with an increase in the incidence of 
SAEs, and despite a modest increase in reported AEs, 
fewer patients discontinued treatment as a result of AEs 
compared with those in the lower-dose (9.5 mg/24 h) 
patch group. An increased incidence of AEs is often asso-
ciated with a dose titration step [37]. AEs in the OPTIMA 
study decreased over time, with a similar incidence of 
most AEs reported in both treatment groups in the sec-
ond half of the DB phase (weeks 25–48). Throughout the 
course of the study, slightly more patients in the higher-
dose group experienced an AE of ‘weight decreased’. The 
potential weight loss in patients receiving the 13.3 mg/24 
h patch may require clinical attention and consideration 
of possible counteracting interventions such as protein-
enriched nutritional supplements. The overall decrease 
in the incidence of AEs observed over time may have 
contributed to the high degree of persistence and low 
rate of discontinuations observed with both patch doses. 
Overall, safety data confirm the good tolerability of the 
rivastigmine patch. The most common AEs were cho-
linergic in nature and were as expected when compared 
with previous studies of rivastigmine treatment, includ-
ing IDEAL [8].
The high-dose rivastigmine patch would enable phy-
sicians to optimize efficacy, while maintaining good tol-
erability, for appropriate patients. Such patients could 
include those who show signs of functional decline on 
current stable therapy, or those whom the physician per-
ceives would gain additional benefit from up-titration, in 
order to achieve optimal efficacy. In all cases, the deci-
sion to up-titrate from the maintenance dose of 9.5 to the 
13.3 mg/24 h patch should be based on good tolerability 
of the current dose and be considered after a minimum 
of 4 weeks of treatment at previous dose levels.
In summary, the OPTIMA study has demonstrated 
higher-dose efficacy of the 13.3 mg/24 h rivastigmine 
patch on functional outcomes, without compromising 
safety and tolerability. These findings are clinically rele-
vant as the higher-dose 13.3 mg/24 h patch demonstrated 
long-term efficacy over the 48-week DB study period and 
an additional benefit over the currently approved mainte-
nance patch dose of 9.5 mg/24 h. The potential to enhance 
functional integrity of the patient could offer important 
benefits, including less dependence on family and/or 
caregivers and the possibility of delayed institutionaliza-
tion [3]. The higher-dose rivastigmine patch would pro-
vide physicians with an additional therapeutic option for 
the treatment of patients with mild-to-moderate AD.
Acknowledgements
The OPTIMA principal investigators are acknowledged 
for their contributions to the study. Editorial assistance was 
provided by Emma East of Fishawack Communications Ltd., 
Oxford, UK; this was funded by Novartis Pharma AG, Basel, 
Switzerland.
Disclosure Statement
This study was funded by Novartis Pharma AG, Basel, 
Switzerland.
J.L.C. has provided consultation to Abbott, Acadia, Adamas, 
Anavex, Astellas, Avanir, Baxter, Bristol-Myers Squibb, Eisai, 
Elan, EnVivo, Forest, Genentech, GlaxoSmithKline, Janssen, 
Ely Lilly, Lundbeck, Medtronics, Merck, Neurokos, Neuronix, 
Novartis, Otsuka, Pain Therapeutics, Pfizer, Plexxicon, Prana, 
QR, Sanofi, Sonexa, Takeda and Toyama pharmaceutical com-
panies. J.L.C. has also provided consultation to Bayer, Avid, GE 
Healthcare, MedAvante, Neurotrax and UBC. J.L.C. owns stock 
in Adamas, Prana, Sonexa, MedAvante, Neurotrax, Neurokos and 
QR Pharma. He has participated as a speaker/lecturer for Eisai, 
Dement Geriatr Cogn Disord 2012;33:341–353352 Cummings et al.
Forest, Janssen, Novartis, Pfizer and Lundbeck. J.L.C. owns the 
copyright of the Neuropsychiatric Inventory. J.L.C. has provided 
expert witness consultation regarding olanzapine and ropinerol.
L.F. has received fees for board membership from Eisai, 
Elan/Wyeth, Eli Lilly, GE Healthcare, Janssen-Cilag, Lundbeck, 
Merz Pharma, Novartis, Pfizer and Schering-Plough. L.F. has 
provided consultation to AstraZeneca, Merz Pharma, Myriad, 
Neurochem, Novartis, Pfizer and Schering-Plough. He has pro-
vided an expert testimony to Apotex Inc. L.F. has also received 
grants or has grants pending from Novartis and Pfizer. He has 
received honoraria from Allergan, Eisai, Elan/Wyeth, Janssen-
Cilag, Lundbeck, Merz Pharma, Neurochem Inc., Novartis and 
Pfizer. L.F. has received payment for the development of edu-
cational presentations including service on speakers’ bureau 
from Novartis. He has also received travel/accommodation ex-
penses from Merz Pharma.
S.E.B., in the last 5 years, has had a financial relationship in the 
form of: contract research funds to the AstraZeneca, Boehringer 
Ingelheim, GlaxoSmithKline, Lundbeck, Myriad, Novartis, 
Novo Nordisk, Pfizer, Cognitive Neurology Research and Stroke 
Research Units from Roche and Sanofi-Aventis;  received speaker’s 
honoraria for continuing medical education from Eisai, Janssen-
Ortho, Lundbeck, Myriad, Novartis and Pfizer, and received 
honoraria for ad hoc consulting from Bristol-Myers Squibb, Elan, 
GlaxoSmithKline, Janssen-Ortho, Lundbeck, Myriad, Novartis, 
Pfizer, Roche, Schering-Plough and Wyeth.
S.B. acted as the main investigator for France. He has no 
current commercial interests; however, in the past 4 years he 
has received honoraria for consulting or paid conferences 
from Eisai, Janssen-Cilag, Lundbeck, Novartis, Roche and 
Sanofi-Aventis.
G.B. has received honoraria from Eli Lilly, Lundbeck, 
Novartis and Pfizer.
J.L.M. has provided scientific advice or has been an in-
vestigator or data monitoring board member for consultancy 
fees from Bayer, Bristol-Myers Squibb, Eisai, GE Healthcare, 
GlaxoSmithKline, Innogenetics, Janssen-Cilag, Lundbeck, 
Merz Pharma, MSD, Novartis, Pfizer and Roche.
R.W.K. has received lecturing fees from Lundbeck, Merz 
Pharma, Novartis and Pfizer.
P.D. is an employee of Novartis Pharmaceuticals Corporation.
A.C. and C.S. are employees of Novartis Pharma AG.
References 
 1 Fan LY, Chiu MJ: Pharmacological treatment 
for Alzheimer’s disease: current approaches 
and future strategies. Acta Neurol Taiwan 
2010;19:228–245.
 2 Razani J, Kakos B, Orieta-Barbalace C, 
Wong JT, Casas R, Lu P, Alessi C, Joseph-
son K: Predicting caregiver burden from 
daily functional abilities of patients with 
mild dementia. J Am Geriatr Soc 2007;55:
1415–1420.
 3 Wattmo C, Wallin AK, Londos E, Minthon 
L: Risk factors for nursing home placement 
in Alzheimer’s disease: a longitudinal study 
of cognition, ADL, service utilization, and 
cholinesterase inhibitor treatment. Geron-
tologist 2011;51:17–27.
 4 Hatoum HT, Thomas SK, Lin SJ, Lane R, 
Bullock R: Predicting time to nursing home 
placement based on activities of daily living 
scores – a modelling analysis using data on 
alzheimer’s disease patients receiving riv-
astigmine or donepezil. J Med Econ 2009;12:
98–103.
 5 Luppa M, Luck T, Brahler E, Konig HH, 
Riedel-Heller SG: Prediction of institutional-
isation in dementia. A systematic review. De-
ment Geriatr Cogn Disord 2008;26:65–78.
 6 Farlow MR, Miller ML, Pejovic V: Treatment 
options in Alzheimer’s disease: maximizing 
benefit, managing expectations. Dement 
Geriatr Cogn Disord 2008;25:408–422.
 7 Rosler M, Retz W, Retz-Junginger P, Dennler 
HJ: Effects of two-year treatment with the 
cholinesterase inhibitor rivastigmine on be-
havioural symptoms in Alzheimer’s disease. 
Behav Neurol 1998;11:211–216.
 8 Winblad B, Cummings J, Andreasen N, 
Grossberg G, Onofrj M, Sadowsky C, Zech-
ner S, Nagel J, Lane R: A six-month double-
blind, randomized, placebo-controlled study 
of a transdermal patch in Alzheimer’s disease 
– rivastigmine patch versus capsule. Int J 
Geriatr Psychiatry 2007;22:456–467.
 9 Exelon patch®. US prescribing information. 
2010. http://www.pharma.us.novartis.com/
product/pi/pdf/exelonpatch.pdf (Accessed 
2nd July 2012).
10 Exelon capsules. US prescribing informa-
tion. 2006. http://www.pharma.us.novartis.
com/product/pi/pdf/exelon.pdf (Accessed 
2nd July 2012).
11 EMEA: Rivastigmine (Exelon®) summary 
of product characteristics. http://www.
emea.europa.eu/docs/en_GB/document_
library/EPAR_-_Product_Information/
human/000169/WC500032598.pdf (Ac-
cessed 2nd July 2012).
12 Emre M, Aarsland D, Albanese A, Byrne EJ, 
Deuschl G, De Deyn PP, Durif F, Kulisevsky 
J, van Laar T, Lees A, Poewe W, Robillard A, 
Rosa MM, Wolters E, Quarg P, Tekin S, Lane 
R: Rivastigmine for dementia associated with 
Parkinson’s disease. N Engl J Med 2004;351:
2509–2518.
13 Olin JT, Aarsland D, Meng X: Rivastigmine 
in the treatment of dementia associated 
with Parkinson’s disease: effects on activities 
of daily living. Dement Geriatr Cogn Disord 
2010;29:510–515.
14 Cummings J, Lefèvre G, Small G, Appel-
Dingemanse S: Pharmacokinetic rationale 
for the rivastigmine patch. Neurology 2007;
69:S10–S13.
15 Kurz A, Farlow M, Lefèvre G: Pharmaco-
kinetics of a novel transdermal rivastig-
mine patch for the treatment of Alzheimer’s 
disease: a review. Int J Clin Pract 2009;63:
799–805.
16 Lefèvre G, Sędek G, Jhee S, Leibowitz M, 
Huang H-LA, Enz A, Maton S, Pommier F, 
Schmidli H, Appel-Dingemanse S: Pharma-
cokinetics and pharmacodynamics of the 
novel daily rivastigmine transdermal patch 
compared with twice-daily capsules in Al-
zheimer’s disease patients. Clin Pharmacol 
Ther 2008;83:106–114.
17 Sadowsky C, Cummings J, Tekin S, Lane R: 
Achieving optimal therapeutic doses – riv-
astigmine (Exelon) patch and capsule (post-
er). 132nd Annu Meet Am Neurol Assoc, 
Washington, October 7–10, 2007.
18 Anand R, Messina J, Hartman R: Dose-
response effect of rivastigmine in the treat-
ment of Alzheimer’s disease. Int J Geriatr 
Psychopharmacol 2000;2:68–72.
19 Grossberg GT, Olin JT, Somogyi M, Meng 
X: Dose effects associated with rivastigmine 
transdermal patch in patients with mild-to-
moderate Alzheimer’s disease. Int J Clin Pract 
2011;65:465–471.
20 Diagnostic and Statistical Manual of Men-
tal Disorders (DSM-IV), ed 4. Washington 
D.C., American Psychiatric Association, 
1994.
Dement Geriatr Cogn Disord 2012;33:341–353 353Efficacy and Safety of Higher-Dose 
Rivastigmine Patch (13.3 mg/24 h) in AD
21 McKhann G, Drachman D, Folstein M, 
Katzman R, Price D, Stadlan EM: Clinical 
diagnosis of Alzheimer disease: report of the 
NINCDS-ADRDA work group under the 
auspices of department of health and human 
services task force on Alzheimer’s disease. 
Neurology 1984;34:939–944.
22 Folstein MF, Folstein SE, McHugh PR: ‘Mini-
mental state’. A practical method for grading 
the cognitive state of patients for the clinician. 
J Psychiatr Res 1975;12:189–198.
23 Galasko D, Bennett D, Sano M, Ernesto C, 
Thomas R, Grundman M, Ferris S: An in-
ventory to assess activities of daily living for 
clinical trials in Alzheimer’s disease. The 
Alzheimer’s Disease Cooperative Study. Al-
zheimer Dis Assoc Disord 1997;11(suppl 2):
S33–S39.
24 Rosen WG, Mohs RC, Davis KL: A new rat-
ing scale for Alzheimer’s disease. Am J Psy-
chiatry 1984;141:1356–1364.
25 Reitan RM: Validity of the trail making test as 
an indicator of organic brain damage. Percept 
Motor Skills 1958;8:271–276.
26 Corrigan JD, Hinkeldey NS: Relationships 
between parts A and B of the Trail Making Test. 
J Clin Psychol 1987;43:402–409.
27 Cummings JL, Mega M, Gray K, Rosenberg-
Thompson S, Carusi DA, Gornbein J: The 
Neuropsychiatric Inventory: comprehensive 
assessment of psychopathology in dementia. 
Neurology 1994;44:2308–2314.
28 Kaufer DI, Cummings JL, Christine D, Bray 
T, Castellon S, Masterman D, MacMillan A, 
Ketchel P, DeKosky ST: Assessing the impact 
of neuropsychiatric symptoms in Alzheim-
er’s disease: the neuropsychiatric inventory 
caregiver distress scale. J Am Geriatr Soc 
1998;46:210–215.
29 Bullock R, Touchon J, Bergman H, Gambina 
G, He Y, Rapatz G, Nagel J, Lane R: Rivastig-
mine and donepezil treatment in moderate to 
moderately-severe Alzheimer’s disease over 
a 2-year period. Curr Med Res Opin 2005;
21:1317–1327.
30 Grossberg GT: Impact of rivastigmine on 
caregiver burden associated with Alzheimer’s 
disease in both informal care and nursing 
home settings. Drugs Aging 2008;25:573–584.
31 Nadkarni NK, Black SE: Cognitive outcomes; 
in Rockwood K, Gauthier S (eds): Trial De-
signs and Outcomes in Dementia Therapeu-
tic Research. Abingdon, Taylor & Francis, 
2006, pp 85–112.
32 Mohs R, Marin D, Green CR, Davis KL: The 
Alzheimer’s Disease Assessment Scale: mod-
ifications that can enhance its use in future 
clinical trials; in Becker R, Giacobini E (eds): 
Alzheimer Disease: From Molecular Biol-
ogy to Therapy. Boston, Birkhäuser, 1996, 
pp 407–412.
33 Rogers SL, Farlow MR, Doody RS, Mohs R, 
Friedhoff LT: A 24-week, double-blind, pla-
cebo-controlled trial of donepezil in patients 
with Alzheimer’s disease. Donepezil Study 
Group. Neurology 1998;50:136–145.
34 Peskind ER, Potkin SG, Pomara N, Ott BR, 
Graham SM, Olin JT, McDonald S: Meman-
tine treatment in mild to moderate Alzheim-
er disease: a 24-week randomized, controlled 
trial. Am J Geriatr Psychiatry 2006;14:
704–715.
35 Raskind MA, Peskind ER, Wessel T, Yuan W: 
Galantamine in AD: a 6-month randomized, 
placebo-controlled trial with a 6-month 
extension. The Galantamine USA-1 Study 
Group. Neurology 2000;54:2261–2268.
36 Small G, Bullock R: Defining optimal treat-
ment with cholinesterase inhibitors in Al-
zheimer’s disease. Alzheimers Dement 2011;
7:177–184.
37 Farlow MR, Salloway S, Tariot PN, Yardley 
J, Moline ML, Wang Q, Brand-Schieber E, 
Zou H, Hsu T, Satlin A: Effectiveness and 
tolerability of high-dose (23 mg/day) ver-
sus standard-dose (10 mg/day) donepezil in 
moderate to severe Alzheimer’s disease: a 24-
week, randomized, double-blind study. Clin 
Ther 2010;32:1234–1251.
